"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Morrhuate Sodium Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Morrhuate Sodium Injection is a sclerosing agent used for the obliteration of primary varicosed veins that consist of simple dilation with competent valves. This medication is available in generic form. Morrhuate sodium injection may cause side effects; consult your doctor.
Dosage of morrhuate sodium injection depends on the size and degree of varicosity. The usual adult dose for obliteration of small or medium veins is 50- 100 mg (1-2 mL of the 5% injection). For large veins, 150- 250 (3-5 mL of the injection) is used. Morrhuate sodium injection may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, morrhuate sodium injection should be used only if prescribed. Consult your doctor before breastfeeding.
Our Morrhuate Sodium Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Morrhuate Sodium FDA Prescribing Information: Side Effects
Additional Morrhuate Sodium Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.